All In Biotech

Investigational drug · Phase 2

RN0361

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertriglyceridemia, Familial Chylomicronemia Syndrome.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "RN0361"

First trial start

2024

Sep 30, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RN0361", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hypertriglyceridemia
  • Familial Chylomicronemia Syndrome

Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "RN0361" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Hypertriglyceridemia

  • SHR-1918Phase 37 trials

    Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia

  • DR10624Phase 35 trials

    Zhejiang Doer Biologics Co., Ltd. · Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)

  • MAR001Phase 23 trials

    Marea Therapeutics · Hypertriglyceridemia

  • RBD5044Phase 22 trials

    Ribocure Pharmaceuticals AB · Dyslipidemias, Hypertriglyceridemia

  • ION775Phase 21 trial

    Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia

  • JMT202Phase 21 trial

    Shanghai JMT-Bio Inc. · Hypertriglyceridemia

  • MN-001Phase 21 trial

    MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.